While the use of NCS1 is currently explored in other indications such as cancer and fragile X syndrome,61, 62, 63 developing therapies with NCS1 as a target in the context of WS is new, and only cell-based studies have been performed so far.11 This evidence concerns the gene NCS1 and fragile X syndrome.